Editas Medicine, Inc.

Hariharan Jayaram

Barrett Ethan Steinberg

Ari E Friedland

John Zuris

Cecilia Cotta-Ramusino

Tongyao Wang

Jennifer Leah Gori

Gordon Grant Welstead

Christopher Borges

Joshua C Tycko

William Selleck, Jr

Nick Huston

Penrose Odonnell

Penrose O'donnell

William Selleck

John Anthony Zuris

CRISPR/Cpf1-related compositions and methods for treatment of cancer.

Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

The present disclosure relates to systems and methods of analyzing cleavage profiles of nucleases.

Assessing nuclease cleavage

Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.

Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA

Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.

Cas9 fusion molecules, gene editing systems, and methods of use thereof

Disclosed herein are compositions and methods for increasing the immunocompatibility of donor cells (e.g., HSCs or T-cells) for transplantation to a recipient subject, as well as database schemes for use in the methods. The methods and compositions described herein result in the allele-specific modification of one or more immunogenicity genes (e.g., an HLA gene) of a cell, resulting in cells that are suitable for transplantation into a recipient subject.

CRISPR/Cas-related methods and compositions for improving transplantation

Disclosed herein are methods for evaluation, selection, optimization, and design of Cas9 molecule/gRNA molecule complexes.

Growing community of inventors

Cambridge, MA, United States of America

Hariharan Jayaram